Breast Cancer Research and Treatment – The use of neoadjuvant systemic therapy for primary breast cancer can achieve tumor shrinkage, enabling less invasive surgical treatments, such as…
Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.
Without a doubt, smoking is the No. 1 cause of lung cancer. But as many as 15% of men and 50% of women who are…
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repai…
Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and comprehensive counseling with tobacco…
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by the OSUCCC – James shows most people continue to…
The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.
Three-year grant of $225,000 to support the salary and benefits of postdoctoral or clinical research fellows conducting lung cancer research.
Cambridge, MA–based Mersana Therapeutics announced today that its B7-H4–targeted antibody–drug conjugate emilatug ledadotin (XMT-1660) elicited a complete response in 23% (six of 26) of patients…
Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative breast cancer (Abstract GS3-03).…
Learn more about the 2025 ASTRO Annual Refresher Course.
